Eli Lilly Foundayo pill cuts sleep apnea severity
Eli Lilly announced that its obesity pill, Foundayo, successfully reduced the severity of obstructive sleep apnea in late-stage clinical trials. The company plans to seek FDA approval for the drug as a treatment for the condition by the end of the year.
Why it matters
This development offers a potential new pharmaceutical treatment for a condition affecting nearly 1 billion people globally, potentially reducing reliance on mechanical breathing devices.
Eli Lilly on Monday said its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea, the most common sleep-related breathing disorder, in patients with obesity, in a late-stage trial.
The drugmaker plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea, or OSA, in adults with obesity or who are overweight. The results make the pill — which rolled out in the U.S. in April — one of several GLP-1 treatments to show promise in treating the condition.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in